NEW YORK (GenomeWeb News) – MDxHealth today announced an agreement with preferred provider organization Stratose that gives its 12.4 million members access to the ConfirmMDx prostate cancer test.

Formerly operating as Coalition America, NPPN, OPPN, PlanCare America, 4MOST Health, Qualident and KeyClaims, Stratose has 850,000 direct and affiliate medical, dental, and workers' compensation provider contracts, MDxHealth said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.